In last trading session, Regenxbio Inc (NASDAQ:RGNX) saw 1.74 million shares changing hands with its beta currently measuring 1.22. Company’s recent per share price level of $11.19 trading at $1.76 or 18.66% at ring of the bell on the day assigns it a market valuation of $553.04M. That closing price of RGNX’s stock is at a discount of -157.37% from its 52-week high price of $28.80 and is indicating a premium of 23.77% from its 52-week low price of $8.53. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.44 million shares which gives us an average trading volume of 473.56K if we extend that period to 3-months.

For Regenxbio Inc (RGNX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.30. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -1.15 in the current quarter.

Regenxbio Inc (NASDAQ:RGNX) trade information

Upright in the green during last session for gaining 18.66%, in the last five days RGNX remained trading in the green while hitting it’s week-highest on Thursday, 11/07/24 when the stock touched $11.19 price level, adding 3.7% to its value on the day. Regenxbio Inc’s shares saw a change of -37.66% in year-to-date performance and have moved 30.27% in past 5-day. Regenxbio Inc (NASDAQ:RGNX) showed a performance of 21.10% in past 30-days. Number of shares sold short was 4.99 million shares which calculate 8.24 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 38 to the stock, which implies a rise of 70.55% to its current value. Analysts have been projecting 18 as a low price target for the stock while placing it at a high target of 40. It follows that stock’s current price would drop -60.86% in reaching the projected high whereas dropping to the targeted low would mean a loss of -60.86% for stock’s current value.

Regenxbio Inc (RGNX) estimates and forecasts

Statistics highlight that Regenxbio Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -28.64% of value to its shares in past 6 months, showing an annual growth rate of 22.43% while that of industry is 16.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 6.40% from the last financial year’s standing.

7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 24.62M for the same. And 5 analysts are in estimates of company making revenue of 21.4M in the next quarter. Company posted 22.21M and 15.62M of sales in current and next quarters respectively a year earlier.

In 2024, company’s earnings growth rate is likely to be around 22.67% while estimates for its earnings growth in next 5 years are of 13.60%.

Regenxbio Inc (NASDAQ:RGNX)’s Major holders

Insiders are in possession of 7.41% of company’s total shares while institution are holding 90.11 percent of that, with stock having share float percentage of 97.32%. Investors also watch the number of corporate investors in a company very closely, which is 90.11% institutions for Regenxbio Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at RGNX for having 8.61 million shares of worth $100.73 million. And as of 2024-06-30, it was holding 18.8252 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 5.11 million shares on 2024-06-30. The number of shares represents firm’s hold over 11.1818 of outstanding shares, having a total worth of $59.83 million.